Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Releases EXOSOMES & MICROVESICLES 2012 Presentation

SAN DIEGO - October 3, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), today released the slide-deck underlying a presentation given yesterday by its Chairman and CEO, Jim Joyce at the EXOSOMES & MICROVESICLES 2012 conference in Orlando, Florida. The presentation was entitled: Extracorporeal clearance of tumor-secreted exosomes as an adjunct to enhance cancer therapy efficacy.

The presentation focused on the potential of the Aethlon Hemopurifier® to be combined with chemo and immunotherapies as a strategy to enhance cancer therapy outcomes. The Hemopurifier®, which is a first-in-class device being advanced in Hepatitis C (HCV) care, has also demonstrated the ability to capture cancer-promoting exosomes secreted by tumors. Tumor-secreted exosomes have emerged to become a potentially vital therapeutic target in cancer as researchers have reported these microvesicular particles promote tumor progression by inducing programmed cell death of anti-cancer immune cells. As a result of inhibiting the immune response, exosomes increase the proliferation and spread of many forms of cancer. Researchers have also reported that exosomes seed the spread of metastasis, promote angiogenesis (essential for tumor survival and growth), increase tumor aggressiveness, and contribute to anti-cancer drug resistance.
The slide-deck of the presentation can be accessed on the Aethlon Medical website here

About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

TSX Tech Stock Trading Alert: Research In Motion (TSX: RIM) Makes Top Trading List

New York, NY - October 2, 2012 (Investorideas.com newswire, www.techsectorstocks.com) Investor Ideas,, a global investor research portal for independent investors, issues a tech stock trading alert for Research In Motion Limited (NASDAQ: RIMM), (TSX:RIM). The stock made the top ten traders list on the TSX, trading at $ 8.240, up 0.550 or 7.15% on 5,781,777 shares.
The company reported second quarter earnings last week.

About Research In Motion
Research In Motion (RIM), a global leader in wireless innovation, revolutionized the mobile industry with the introduction of the BlackBerry(R) solution in 1999. Today, BlackBerry products and services are used by millions of customers around the world to stay connected to the people and content that matter most throughout their day. Founded in 1984 and based in Waterloo, Ontario, RIM operates offices in North America, Europe, Asia Pacific and Latin America. RIM is listed on the NASDAQ Stock Market (RIMM) and the Toronto Stock Exchange (RIM.TO). For more information, visit www.rim.com or www.blackberry.com.
About TSX
http://www.tmx.com/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts. Sectors include biotech stocks, tech stocks, beverage stocks, mining stocks, water, renewable energy, oil and gas.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 14 of the best stock directories online;
Research tech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411 - Source - www.Investorideas.com

Biotech Stock Breaking News; Aethlon Medical (OTCBB: AEMD) Releases Hepatitis C Virus (HCV) Treatment Protocol and Inclusion/Exclusion Criteria Underlying Compassionate-Use Commercialization Program

SAN DIEGO - October 2, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today released the treatment protocol underlying a program that will provide hard-to-treat HCV-infected individuals with expanded access to Hemopurifier® therapy. The Company also disclosed inclusion and exclusion criteria for candidate patients as well as details on the physicians who will administer the program, which is expected to generate first product sales of the Aethlon Hemopurifier®.

The Aethlon Hemopurifier® is a first-in-class medical device with broad-spectrum capability to address infectious viral pathogens and immunosuppressive exosomes underlying cancer and other life-threatening conditions. In the expanded access program, Hemopurifier® therapy will be administered to selectively target the rapid clearance of HCV from the entire circulatory system to improve benefit, dose, duration and tolerability of standard-of-care drug therapy. The program is being initiated with support from the Institutional Review Board at the Medanta Medicity Institute (Medicity) to allow compassionate usage of the Aethlon Hemopurifier® for individuals who previously failed or subsequently relapsed standard-of-care drug regimens. The Medicity is a leading center for medical tourism in India.
In addition to offering Hemopurifier® therapy to the citizens of India, HCV-infected individuals from the United States, European Union and other regions of the world may pursue treatment through the expanded access program. It is estimated that approximately 170 million people worldwide are infected with HCV, which leads to chronic liver disease or cirrhosis, and is a leading cause of liver transplantation.
"We are grateful for the opportunity to provide hard-to-treat HCV-infected individuals with access to Hemopurifier® therapy," stated Aethlon Chairman and CEO, Jim Joyce. "Beyond advancing our therapeutic objectives, the resulting Hemopurifier® product sales will augment the government contract revenue stream we established this past year."

The Medicity Expanded Access Treatment Protocol
The Medicity expanded access program will offer HCV-infected individuals the option of either a 3-day or 7-day Hemopurifier® therapy regimen. Under each regimen, Hemopurifier® therapy will be administered continuously for a period up to six hours on each treatment day. While there will be a difference in cost, Hemopurifier® therapy underlying both regimens will be initiated in combination with standard-of-care drug therapy. The treatment objective will be to accelerate the rate and increase the likelihood that patients achieve undetectable HCV RNA. Details related to therapy pricing and candidate patient enrollment processes at the Medicity are anticipated in the coming weeks.
Candidate Patient Inclusion Criteria

• Males or females 18 years of age and older testing positive for any HCV genotype
• HCV-infected individuals that have relapsed after completing a previous course of standard-of-care drug therapy
• Null responders or individuals who previously were unable to achieve > 2 log viral load reduction at month three of standard of care drug therapy
• Candidate patients must be willing to submit to temporary vascular access catheterization
• Ability to tolerate blood volume losses of up to 150 ml per week
• Stable clinical condition, including stable hematocrit
• Individuals on ACE inhibitors must suspend ACE inhibitor administration for a minimum of six days prior to initiating therapy
• Karnofsky score = 60
• Details of blood chemistry inclusion criteria will be provided to candidate patients who meet the above criteria
• Candidate patients will be required to sign a written informed consent prior to enrollment in the treatment access program

Candidate Patient Exclusion Criteria

• Clinically significant infection, other than HCV, defined as any acute viral, bacterial, or fungal infection, which requires specific therapy (Anti-infectious therapy must have been completed at least 14-days before entry into study)
• Co-infections with Hepatitis B virus and Human immunodeficiency virus (HIV)
• Received any investigational drug agent(s) within 28-days of entry into study
• Any known pre-existing medical condition that could interfere with the subject's participation in the protocol, including serious psychiatric disorders, CNS trauma or active seizure disorders requiring medication, poorly controlled diabetes mellitus, significant cardiovascular dysfunction within the past 6 months (e.g., angina, congestive heart failure, recent myocardial infarction, severe hypotension, or significant arrhythmia)
• Subjects with ECG showing clinically significant abnormalities
• Need for frequent blood transfusions.
• Recent History of bleeding or bleeding disorders requiring the restriction in use of anticoagulants during study treatments.
• Active immunologically mediated disease (e.g., inflammatory bowel disease [Crohn's disease, ulcerative colitis], rheumatoid arthritis, idiopathic thrombocytopenia purpura, systemic lupus erythematosus, autoimmune or inherited hemolytic anemia, scleroderma, severe psoriasis)
• Any medical condition requiring, or likely to require during the course of the study, chronic systemic administration of steroids or other immune-regulatory medications
• Substance abuse, such as alcohol (~80 gm/day), IV drugs, and inhaled drugs (If the subject has a history of substance abuse, to be considered for inclusion into the protocol, the subject must have abstained from using the abused substance for at least 2 months
• Any cancer requiring systemic chemotherapy
• Any other condition that, in the opinion of the principal investigators or treating physicians, would make the subject unsuitable for enrollment, or could interfere with the subject participating in and completing the expanded access protocol

Current HCV Studies
In addition to the forthcoming expanded access program, Aethlon has been conducting a study at the Medicity which is evaluating the capability of the Aethlon Hemopurifier® to accelerate HCV RNA depletion at the outset of standard of care peginterferon+ribavirin (PR) therapy. Specifically, HCV-infected individuals are enrolled to receive up to three, six-hour Hemopurifier® treatments during the first three days of PR drug therapy. Aethlon recently reported that two HCV-infected patients who received Hemopurifier® therapy in combination with PR drug therapy achieved undetectable viral load at day-7, which is rarely reported in drug therapy alone.
A primary clinical endpoint of the Medicity protocol has been to increase the incidence of rapid virologic response (RVR), defined as undetectable HCV RNA at day 30 of therapy. RVR represents the clinical endpoint that best predicts treatment cure, otherwise known as sustained virologic response (SVR), defined as undetectable HCV RNA 24-weeks after the completion of PR drug therapy. As a point of reference, the landmark IDEAL Study of 3,070 HCV genotype-1 patients documented that only 10.35% (n=318/3070) of PR treated patients achieved a RVR. However, patients that achieved a RVR had SVR rates of 86.2% (n=274/318) versus SVR rates of 32.5% (n=897/2752) in non-RVR patients. While the incidence of undetectable HCV RNA at day-7 is not reported in the IDEAL study, the study did reveal that just 4.3% (n=131/3070) of patients achieved undetectable HCV RNA at day-14, which equated to a 91% (n=118/131) SVR rate.
Aethlon reported that Hemopurifier® therapy has been well tolerated and without device-related adverse events in ten treated patients. Of these ten patients, seven patients were infected with HCV genotype-1; two patients were infected with HCV genotype-3; and one patient was infected with HCV genotype-5. At present, undetectable HCV RNA is reported in eight of the 10 treated patients. Of the two patients with detectable HCV RNA, one discontinued PR therapy as a result of a diabetes related condition. HCV RNA is undetectable in all patients (n=4) that have been monitored for 48 weeks since receiving Hemopurifier® therapy. Among the 10 treated patients, Aethlon reported that six genotype-1 patients received the three treatment Hemopurifier® protocol, which resulted in four (67%) patients achieving a RVR. The IDEAL study predicts it would normally require approximately 40 PR treated patients to achieve 4 RVR outcomes. Both patients who achieved undetectable HCV RNA at day-7 also achieved a RVR. Beyond the high likelihood of a SVR, genotype-1 patients that achieve a RVR also have the opportunity to reduce the duration of PR drug therapy from 48 weeks to 24 weeks.
About Medanta – The Medicity
Medanta – The Medicity is one of India's largest multi-super specialty institutes located in Gurgaon, a bustling town in the National Capital Region. Founded by eminent cardiac surgeon, Dr. Naresh Trehan, the institution has been envisioned with the aim of bringing to India the highest standards of medical care along with clinical research, education and training. Medanta is governed under the guiding principles of providing medical services to patients with care, compassion and commitment.
Spread across 43 acres, the institute includes a research center, medical and nursing school. It has 1250 beds and over 350 critical care beds with 45 operation theatres catering to over 20 specialties. Medanta houses six centers of excellence, which provide medical intelligentsia, cutting-edge technology and state-of-the-art infrastructure with a well-integrated and comprehensive information system. The Medicity brings together an outstanding pool of doctors, scientists and clinical researchers to foster collaborative, multidisciplinary investigation, inspiring new ideas and discoveries; and translating scientific advances more swiftly into new ways of diagnosing and treating patients and preventing diseases. A one-of-its-kind facility across the world, Medanta through its research integrates modern and traditional forms of medicine to provide accessible and affordable healthcare.
The Medicity Expanded Access Program Physicians
Dr. Vijay Kher - Chairman, Division of Nephrology, Kidney & Urology Institute
Dr. Vijay Kher is currently Chairman, Division of Nephrology, Medanta Kidney & Urology Institute. Dr. Kher has established Academic & Clinical departments of Nephrology at Shere-Kashmir, Institute of Medical Sciences in Srinagar, SGPGIMS Lucknow, Apollo Hospitals, New Delhi, Fortis group of hospitals NCR, Delhi & now at Medanta. His research interests are kidney transplantation (clinical immunosuppression, pre emptive kidney transplantation & steroid free immunosuppression, cost-containment), progression of renal disease, acute kidney injury and glomerulonephritis. An astute clinician, a teacher par excellence and a keen researcher, Dr. Kher combines these assets with a friendly and inclusive demeanor to inspire the Nephrology fraternity in India by his professional dedication, academic excellence and social responsibility. He has been awarded fellowships of National Academy of Medical Sciences, Royal College of Physicians Edinburg & Indian Society of Nephrology. Dr. Kher has published more than 150 papers in peer-reviewed journals, 24 book chapters and has edited 5 books.
Dr. Randhir Sud - Chairman, Medanta Institute of Digestive & Hepatobiliary Sciences
Dr. Sud is Chairman of The Medanta Institute of Digestive & Hepatobiliary Sciences, which is a dedicated facility for patients with gastrointestinal, liver, pancreatic and biliary diseases, There are multiple treatment options for a disease and to provide the best available treatment to patients, this Institute has devised protocols where medical, surgical and allied teams jointly decide patient treatments and management.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

Entertainment News: Rhode Island filmmaker Chad A. Verdi's film LOOSIES premieres on Showtime Oct 4th

EAST GREENWICH, RI - October 2, 2012 (Investorideas.com Newswire) Verdi Productions and the Woodhaven Production Company are pleased to announce the cable premiere of their film Loosies. Loosies will be shown worldwide by the Showtime network starting Oct 4th. Showtime acquired the paid cable rights earlier this year. Screen Media of NY has acquired Verdi's latest two films, Infected and Self-Storage. Infected will premiere at Rock and Shock on Oct 13th and will hit select theaters on Oct 25th. A special sneak peek of Self Storage will follow the Infected premiere and be released in select theaters in the first quarter of 2013.

Loosies, which was released theatrically earlier this year by IFC, tells the story of Bobby (Peter Facinelli), a NYC pickpocket passing as a Wall Street stockbroker who roams the city looking for marks. He must face reality when an old fling informs him she's pregnant, and the baby is his. Suddenly, two different worlds collide, forcing Bobby to reevaluate a lifetime of missteps, and make a big decision about his future.
The film stars Peter Facinelli (Twilight, Nurse Jackie, The Scorpion King), Jaimie Alexander (Thor, Rest Stop, Hallowed Ground), Vincent Gallo (Buffalo '66, The Brown Bunny, Tetro), Michael Madsen (Reservoir Dogs, Kill Bill Vol. 1 & 2), and Joe Pantoliano (Memento, The Matrix, The Fugitive). The original soundtrack was composed and performed by Paul McDonald (American Idol), an original score by Chad Fischer ( Garden State ), and music supervision by Michelle Verdi, head of music and talent for both Verdi Productions and the Woodhaven Production Company.
Infected, a horror/zombie thriller set in the woods of New England, centers around Terry, an absentee father (Michael Madsen), and his son Andrew (Tom DeNucci -Inkubus, Loosies) who must fight for survival when their small, close-knit hunting group becomes infected with a virus that originated from a rabid deer they killed and consumed. This infection causes the crew, including Doctor Denehey (William Forsythe), to become homicidal and violent and gives them an insatiable, cannibalistic thirst for humans. In this modern day Night of The Living Dead, the father and son duo are forced to relinquish old friendships as their former hunting buddies become... Infected.
Self Storage, written by Rhode Island actor/writer/producer Tom DeNucci (Inkubus, Loosies, Infected), tells the story of Jake, the night watchman working at a highly secured self storage facility. His pals are home from college and looking to party. Jake (Tom DeNucci) invites them to his work for a fiesta of his own. Innocent mischief turns a naughty night of sex, drugs and rock and roll into an evening of pure terror. Barbed wire fences are meant to keep people OUT. But these fences keep people IN. Eric Roberts plays the role of Walter, a former black operative with an evil secret. Walter, along with his faithful brother at arms, Trevor (Michael Berryman), has some unfinished business with a seedy underworld grifter, Jonah(Jonathan Silverman). Black market business mixes with pleasure when Jake and his pals stumble upon this heinous covert operation.
Verdi stated, "Making four films over the last 24 months is one thing, but selling all four films and having the success they are receiving is simply mind blowing." Verdi added, "the landscape of filmmaking is changing daily. It's all about distribution and being able to get your product in front of as many people as possible and as quickly as possible, that's what Screen Media brings to the table. The days of small independent films spending tens of millions of dollars for their films to hit theaters is long gone. It was replaced by VOD and the ability of streaming video both at home and on handheld devices. Our goal was met when we received a national VOD release that reached over 100 million homes for both Inkubus and Loosies. That is what Screen Media was able to do with our first film Inkubus through Universal and what IFC did with Loosies.
Woodhaven released Inkubus, a slasher flick starring horror icon Robert Englund (the original Freddy Krueger), in theaters last Halloween to sell-out crowds. DVDs hit stores nationwide February 21st. The film has now sold more than 100 thousand units through outlets like Wal-Mart, RedBox, and Amazon and is currently on VOD.
The Woodhaven Production Company, a subsidiary of Verdi Productions, is a fully funded film production company, covering all aspects of filmmaking from conception of script through post production.
For further information please contact woodhavenproductioncompany@gmail.com or visit Woodhaven on the web at www.woodhavenfilms.com.
Follow "INKUBUS" on Facebook and Twitter: www.facebook.com/inkubusmovie or www.twitter.com/inkubusthemovie
Rock and Shock info: http://rockandshock.com
Like INFECTED and SELF STORAGE on Facebook
http://www.facebook.com/Selfstoragethemovie?fref=ts
http://www.facebook.com/Infectedthemovie?fref=ts
http://www.imdb.com/name/nm3838148/
http://www.imdb.com/name/nm40900
Contact Information
Chad A. Verdi
CEO
http://www.imdb.com/name/nm3838148/
Michelle L. Verdi
Music and Talent Supervisor Media
http://www.imdb.com/name/nm4090091
Media contact:
Tony Verdi
Director of Communications
401.225.7800
Chad A. Verdi
Producer
President, Verdi Productions & The Woodhaven Production Company
253 Main Street
East Greenwich, RI 02818
Verdifilms.com
Woodhavenfilms.com

Ceradyne (NasdaqGS: CRDN) Makes NASDAQ Top Gainer List on 3M Acquisition

New York, New York - October 1, 2012 (www.investorideas.com newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector for independent investors reports on the top percentage gainer on the NASDAQ for Monday October 1 st. Ceradyne Inc. (NasdaqGS: CRDN) leads NASDAQ, trading at $34.92, gaining $10.49 or 42.94% as of 1:45PM EDT on over 12.4 Million shares. The stock moved on news of a takeover by 3M (NYSE:MMM).
3M (MMM) and Ceradyne, Inc. (CRDN) announced today that they have entered into a definitive agreement for 3M’s acquisition of Ceradyne, Inc. for $35.00 per share. The proposed transaction has an aggregate value of approximately $860 million, or approximately $670 million net of cash, cash equivalents, short-term investments and debt acquired.
About NASDAQ
http://www.nasdaq.com/
About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 13 online stock directories 24/7 - water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Biodefense Stock Trading Alert: PositiveID (OTCBB: PSID) Up 15%

New York, NY - October 1, 2012 (Investorideas.com Newswire, www.biodefensestocks.com) Investorideas.com, a leader in research for independent investors issues a trading alert for biodefense stock, PositiveID Corporation (OTCBB: PSID), trading up at $0.0260, gaining 0.0035 or 15.56% as of 11:16AM EDT on over 758,000 shares. The stock had a morning high of $0.0270.
Last week the Company released an update to shareholders on its pursuit of BioWatch Generation 3, Phase II. Two weeks ago, the Department of Homeland Security ("DHS") revised its procurement strategy for BioWatch Generation 3, Phase II, which now will consist of a two-stage procurement which includes two to three years of testing estimated at $89 million. A draft request for proposal ("RFP") on this effort is scheduled for release in the fourth quarter of calendar 2012. PositiveID's patented M-BAND biodetector was developed under a competitive award from the DHS Science & Technology Directorate ("S&T").
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.www.PositiveIDCorp.com.

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact
PSID:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Investorideas.com:
Contact: 800 665 0411

Tech Stock Breaking News: Research In Motion (RIMM) Second Quarter Results Start a Rally

New York, NY - September 28, 2012 (Investorideas.com newswire, www.techsectorstocks.com) Investor Ideas, a global investor research portal for independent investors, issues a tech stock trading alert for Research In Motion Limited (NASDAQ: RIMM), (TSX:RIM) following second quarter results that were better than the street expected. Investors love an underdog that performs and the market pre-open is seeing a surge in the stock price. The stock is up over 15% before the bell from its close of $7.14.

Highlights:

• BlackBerry subscriber base increased to approximately 80 million global subscribers
• Cash, cash equivalents, short-term and long-term investments increased by approximately $100 million to $2.3 billion at the end of the second quarter
• Cash flow from operations was approximately $432 million in the second quarter
• Revenue of $2.9 billion in Q2, up 2% from $2.8 billion in Q1
• GAAP net loss in Q2 of $235 million, or $0.45 per share diluted, including $136 million in pre-tax restructuring costs; adjusted net loss of $142 million, or $0.27 per share diluted
• Shipments of BlackBerry smartphones were 7.4 million and shipments of BlackBerry PlayBook tablets were approximately 130,000

About Research In Motion
Research In Motion (RIM), a global leader in wireless innovation, revolutionized the mobile industry with the introduction of the BlackBerry(R) solution in 1999. Today, BlackBerry products and services are used by millions of customers around the world to stay connected to the people and content that matter most throughout their day. Founded in 1984 and based in Waterloo, Ontario, RIM operates offices in North America, Europe, Asia Pacific and Latin America. RIM is listed on the NASDAQ Stock Market (RIMM) and the Toronto Stock Exchange (RIM.TO). For more information, visit www.rim.com or www.blackberry.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts. Sectors include biotech stocks, tech stocks, beverage stocks, mining stocks, water, renewable energy, oil and gas.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 14 of the best stock directories online;
Research tech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411 - Source - www.Investorideas.com

Neil Berlant Gives his List of Water Stocks to Watch as Drought Continues

New York NY - September 28, 2012 (Investorideas.com water newswire, www.water-stocks.com) Investorideas.com staff: Investorideas.com, a leader in sector research including water stocks issues a sector snapshot of water stocks to follow as the drought conditions continue to worsen. Reuters, quoting data from the US Drought Monitor noted, " The total extent of drought across the region is more than double > what it was last year, when it reached 29.1% September 27, 2011."

Global drought conditions have affected the price of corn, soybean and wheat and now as a result causing concerns over the price of bacon .
Looking at the water sector, just like every major problem that occurs, there is a group of companies that can and will benefit .
Neil D Berlant of "Profiting From Water, Business and Investment Opportunities in Water ", a well- known and quoted expert in the sector says the following stocks are among the likely long-term beneficiaries :
Trading as of the close September 27 th - note all stocks closed to the upside
Badger Meter Inc. (NYSE BMI) closed at $36.95, up 0.06 or 0.16%
Calgon Carbon Corporation (NYSE :CCC) ended the day at $14.28 up 0.07 or 0.49%
Energy Recovery, Inc. (NasdaqGS :ERII) finished at $2.98, up 0.11 or 3.83%
Heckmann (NYSE :HEK) closed up at $4.36, up 0.26 or 6.34% and continued its gains in after hours trading
Itron (NasdaqGS :ITRI) ended trading at $43.02, up 0.56 or 1.32%
Layne Christensen Co. (NasdaqGS :LAYN) finished at $20.17, up 0.15 or 0.75%
Lindsay Corporation (NYSE :LNN) ended at $71.00 , up 1.77 or 2.56%
Mueller Water Products (NYSE :MWA) ended at $4.85, up 0.10 or 2.11%
Northwest Pipe Co. (NasdaqGS :NWPX) closed at $25.18, up 0.17 or 0.68%
Toro Co. (NYSE :TTC) ended at $39.23, up 1.65 or 4.39%
Valmont Industries, Inc. (NYSE:VMI)closed at $129.60 , up 0.36 or 0.28%
About Neil Berlant
Since 1968, Neil has been continuously involved in the investment banking industry, either as a principal, officer, or founder of several firms. He has supervised and initiated the publication of numerous investment research reports on the water industry and conducted conferences directed towards top corporate management, the investment community, and venture capitalists. He has been a speaker at conferences on topics ranging from financing, to business and investment opportunities in the water industry. In addition, he has consulted to Fortune 500 companies and participated in negotiations concerning mergers, acquisitions, and venture capital investments. He is quoted frequently in newspapers including the Wall Street Journal, The New York Times, Los Angeles Times, Investor's Business Daily, and frequently appears on CNBC and other stations.
Research water stocks with the water stocks directory - one of the most comprehensive water stocks directories online for investors
http://www.investorideas.com/Water-Stocks/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online stock directories 24/7 - water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For More Information Contact:
800 665 0411
Source: Water-Stocks.com, Investorideas.com

Investorideas.com Collaborates with Green Giant Venture Fund to Introduce Carbon Credit Funding

New York, NY - September 27, 2012 (Investorideas.com renewable energy newswire) Investorideas.com, a leader in renewable energy stock research issues a profile on a new featured funding source for carbon credit funding.

Investor Ideas working in collaboration Green Giant Venture Fund is pleased to announce an exclusive financing vehicle available for companies both private or public that are committed to reducing emissions.
The first stage of this process is the development of a Climate Action Plan applicable to almost any company committed to reducing emissions by implementing various changes ranging from even the most basic Energy Efficiency to more complicated waste disposal processes.
After development and implementation of the climate action plan the next step is the development of the actual Carbon and or Emission Credit documentation from the United Nations Framework Convention on Climate Change commonly called the Project Design Document or PDD.
During the development of PDD the quantity and value of the Carbon and or Emission credits are determined.
These Credits are sold forward at a 50% discount from current price via our exclusive Carbon / Emission Credit Forward Contract.
Credits can be quoted on either NYSE Blue (owned by NYSE Euro Next) and or APX Environmental Markets.
Investorideas.com also has created a funding directory featuring over 500 global green funding sources including funds, investors and investment banking firms as well as venture capital.
http://www.investorideas.com/ Funds-and-Venture-Capital-Investing.asp
Profile - Learn more about carbon funding
http://www.investorideas.com/CO/GGVF/
About Investorideas.com - a leader in cleantech investor research
www.Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Join Investor Ideas Get 14 of the best stock directories online;
Research tech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more or get each directory separately in PDF format
Join: http://www.investorideas.com/membership/
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp Investorideas.com was not compensated for this report and does not hold a position in the stock
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com
contact:
800.665.0411

Mining Stock News: SilverCrest (TSX.V: SVL) Reports High Grade Surface Sampling and Additional Drill Results - 157m @ 94.1 gpt Ag Eq* at La Joya

VANCOUVER, BC - September 27, 2012 (Investorideas.com Mining Stocks Newswire) SilverCrest Mines Inc. (TSX-V:SVL)(NYSE MKT:SVLC) (the "Company") is pleased to announce the results of an additional 15 holes of the Phase II drill program and additional surface sampling currently underway at its La Joya Property in Durango, Mexico. The Phase II drill program has been expanded by 10 holes to 90 holes totaling 20,000 metres. Phase II drilling reported to date has extended the Main Mineralized Trend ("Trend") beyond the area containing the current Inferred Resource of 101.9 million ounces Ag Eq.*(see News releases dated March 20 and May 7, 2012 and attached figure). Newly constructed drill roads have exposed high grade surface mineralization with Ag Eq values ranging from 72.6 grams to 187.6 grams over sample intervals ranging from 39.7 metres to 99 metres. Drilling and surface sampling has now extended the Trend to approximately 2.5 kilometres with an average width of approximately 700 metres. Please reference our revised website at www.silvercrestmines.com for more information, photos and figures on La Joya.

J. Scott Drever, President stated: "Since announcing the Inferred Resource of more than 100 million ounces Ag Eq. at La Joya, we have completed an additional 64 core holes in the expanded Phase II program of 70 core and 20 RVC holes. The drill results continue to support our large tonnage silver deposit model and the extensive surface sampling in conjunction with certain drill holes support the concept of a potentially higher grade, open pit concept. The remaining drill holes will be directed to establishing additional resources and a basis for a conceptual open pit evaluation."
Drilling and surface sampling confirms the presence of multiple mineralized systems with metal content dependent on proximity to an underlying intensive body which comes to surface in the southwest portion of the Trend. There is distinct zonation of metals both vertically and laterally that has created an Ag, Au, Cu zone along the main portion of the Trend and a near surface tungsten (W), Cu, Au zone on the southwest portion of the Trend. Tungsten mineralization adjacent to the intrusive(s) is found in virtually all the holes drilled to date.
Five of the 15 holes reported in the tables and text below continued to test the southern extension of the Trend and the remaining 10 holes focused on the delineation of the Contact Zone within the Trend and Santo Nino Target. An extensive, channel surface sampling program along new road cuts has been completed within the Trend and subsequent Contact Zone area with 196 recent assay results. Composites of the surface sampling results are presented in the Tables below and attached figure.
Silver values in this series of core holes and surface channel samples along the Trend range from 1.6 gpt to 119.1 gpt and on a silver equivalent* basis values range from 11.0 gpt to 200.3 gpt Ag Eq. Mineralized intervals range from 8.9 metres to 305.0 metres. True thicknesses of mineralized intercepts can be approximated from cross sections of previously announced drill holes in associated areas. The most significant assay results are shown in the following tables;
Main Mineralized Trend (Ag, Au, Cu)

* Silver equivalency includes silver, gold and copper and excludes lead, zinc, molybdenum, tin and tungsten values. Ag:Au is 50:1, Ag:Cu is 86:1, based on 5 year historic metal price trends of US$24/oz silver, US$1200/oz gold, US$3/lb copper. 100% metallurgical recovery is assumed. All numbers are rounded.

Intervals are sampled or drilled widths. True thicknesses of mineralized intercepts can be approximated from cross sections of previously announced drill holes in associated areas

All sample analyses presented in this news release were completed by ALS Chemex in Zacatecas, Mexico and North Vancouver, BC, Canada.
Mineralized Trend Surface Sampling
Continuous surface channel sampling along newly cut access roads has helped define the potential of near-surface higher grade Ag-Au-Cu mineralization in the central and southern areas of the Trend. Results represent new surface exposures of both manto and structure/stockwork related mineralization with up to 99 metres grading 116.8 gpt Ag, 0.32 gpt Au, 0.63% Cu or 187.6 gpt Ag Eq.

* Silver equivalency includes silver, gold and copper and excludes lead, zinc, molybdenum, tin and tungsten values. Ag:Au is 50:1, Ag:Cu is 86:1, based on 5 year historic metal price trends of US$24/oz silver, US$1200/oz gold, US$3/lb copper. 100% metallurgical recovery is assumed. All numbers are rounded.

Intervals are sampled or drilled widths. True thicknesses of mineralized intercepts can be approximated from cross sections of previously announced drill holes in associated areas.

Contact Zone (W, Cu, Au) and Santo Nino Target (massive sulphides, W, Cu)
Eight holes were drilled on the near-surface portion of the Contact Zone which is located within the Trend boundaries but is a separate target from the manto and structure mineralization. The Trend mineralization is located geologically and vertically above the Contact Zone. The Contact Zone mineralization consists of skarning with stockwork veining and occurs adjacent to intrusive stock and dykes which are exposed at surface in the southwestern portion of the Trend. Copper and gold values appear to be higher on the eastern edge of the Contact Zone compared to the western edge. Contact Zone holes also contain anomalous Pb, Zn, Mo and Sn.
Partial drilling of the Contact Zone shows consistent intercepts of wide-spread tungsten (W03), gold (Au), copper (Cu) mineralization from surface to depth (up to approximately 300 metres vertical). All drilling to date that has intercepted intrusive(s) has also intercepted the Contact Zone over an area of approximately 2.5 kilometres by 1.2 kilometre with estimated thicknesses ranging from 10 to 200 metres. The Contact Zone is considered a "potential large bulk tonnage tungsten target" which will be presented in the next resource estimation due in Q4 2012. Continuous channel sampling along new access roads shows tungsten mineralization up to 305 metres grading 0.063% W03 with anomalous grades of Au, Cu, Ag (see Table below and attached Figure).
Hole L J DD12-74 was drilled on the Santo Nino Target approximately 1 kilometre east of the Trend and intercepted 35.2 metres of massive and semi-massive sulphides grading 52.2 gpt Ag, 0.05 gpt Au and 1.6% Cu with 0.037% W03. This is considered a new discovery at La Joya. Further drilling is planned to determine the dimensions of this mineralization.
Contact Zone and Santo Nino Target (W, Cu, Au)

* Silver equivalency includes silver, gold and copper and excludes lead, zinc, molybdenum, tin and tungsten values. Ag:Au is 50:1, Ag:Cu is 86:1, based on 5 year historic metal price trends of US$24/oz silver, US$1200/oz gold, US$3/lb copper. 100% metallurgical recovery is assumed. All numbers are rounded.

Intervals are sampled or drilled widths. True thicknesses of mineralized intercepts can be approximated from cross sections of previously announced drill holes in associated areas.

Near surface tungsten/molybdenum mineralization encountered in both the Contact Zone and at the adjacent Coloradito target have grades similar to current economic or potentially economic near surface bulk tonnage deposits such as Thompson Creek Mine, ID (0.046 to 0.081 % Mo), Endako, BC (0.030 to 0.046 % Mo) Sisson, NB (0.031% Mo, 0.094% WO3), and El Creston, Mexico (0.071% Mo, 0.06% Cu). All references are from public company websites. Tungsten mineralization at the Coloradito target is up to 116 metres thick grading 0.048% Mo to 0.098% WO3.
Hole L J DD12-67 and L J DD12-69 encountered only intrusive and showed no significant mineralization.
The Phase II drill program is designed to test approximately 2.5 kilometres of the Trend which includes at least 8 near-vertical structures/stockwork zones, 14 near-horizontal, stacked mantos plus the Contact Zone which is adjacent to the underlying intrusive. Drilling on the southern extension of the Trend and Contact Zone continues with three core drill rigs. A reverse circulation drill is expected to be added in October 2012. Based on Company surface mapping, sampling and historic drill hole results, the southern area is thought to be potentially the highest grade area along the Trend. The Company is currently examining the potential for a near-surface, higher grade, low strip open pit as a conceptual "starter pit" that will be evaluated in an upcoming Preliminary Economic Assessment.
Core samples for holes L J DD12-75 to L J DD12-90 are currently being logged, sampled or are in the laboratory for analysis. The Company is currently drilling hole L JDD12-93 located on the southern part of the Trend. Assays for the next series of holes will be reported upon receipt and compilation. Several holes contain anomalous molybdenum, tungsten, tin, lead and zinc values over significant widths in the skarn. The significance of these associated mineral zones is being examined with partial near-surface tungsten results presented in the Table above.
The La Joya Deposit (Mineral Mineralized Trend) currently has estimated Inferred Resources of:

* Silver equivalency includes silver, gold and copper and excludes lead, zinc, molybdenum and tungsten values. Ag:Au is 50:1, Ag:Cu is 86:1, based on 5 year historic metal price trends of US$24/oz silver, US$1200/oz gold, US$3/lb copper. 100% metallurgical recovery is assumed.

**Classified by EBA, A Tetra Tech Company and conforms to NI 43-101, 43-101CP, and CIM definitions for resources. All numbers are rounded. Inferred Resources have been estimated from geological evidence and limited sampling and must be treated with a lower level of confidence than Measured and Indicated Resources.

*** Mineralization boundaries used in the interpretation of the geological model and resource estimates are based on cutoff grades of 15 gpt Ag Eq and 30 gpt Ag Eq using the metal price ratios described above.

Please refer to the January 4, 2012 news release and to the La Joya NI 43-101 Technical Report dated February 20, 2012 for further details of the Inferred Resource estimate.
The core drilling of the Phase II drill program is anticipated to be complete in October, 2012 with a subsequent revision and announcement of updated resources in Q4 2012. Extensive metallurgical test work is underway to examine the amenability and potential metallurgical recoveries of Ag, Au, Cu, W, Mo, Sn, Zn and Pb. Test work results will be presented in the next NI 43-101 Technical Report.
The current NI43-101 resource estimate for La Joya is 101.9 million ounces of silver equivalent as set out in the table above. Based on the current geologic model, drilling and sampling from the Phase I & II programs it is reasonable that the recently discovered mineralized systems could potentially result in a 50 to 100% increase in current inferred mineral resources. This potential increase in resources is conceptual in nature and insufficient exploration has been completed to define the additional mineral resource. It is uncertain that further exploration will result in the recently discovered mineralized systems being delineated as a new mineral resource.
The Qualified Person under National Instrument (NI 43-101) Standards of Disclosure for Mineral Projects for this News Release is N. Eric Fier, CPG, P.Eng, and Chief Operating Officer for SilverCrest Mines Inc., who has reviewed and approved its contents.
SilverCrest Mines Inc. (TSX-V: SVL; NYSE MKT: SVLC) is a Mexican precious metals producer with headquarters based in Vancouver, BC. SilverCrest’s flagship property is the 100%-owned Santa Elena Mine, which is located 150 km northeast of Hermosillo, near Banamichi in the State of Sonora, México. The mine is a high-grade, epithermal gold and silver producer, with an estimated life of mine cash cost of US$8 per ounce of silver equivalent (55:1 Ag:Au). SilverCrest anticipates that the 2,500 tonnes per day facility should recover approximately 4,805,000 ounces of silver and 179,000 ounces of gold over the 6.5 year life of the open pit phase of the Santa Elena Mine. A three year expansion plan is underway to double metals production at the Santa Elena Mine and exploration programs are rapidly advancing the definition of a large polymetallic deposit at the La Joya property in Durango State.
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" within the meaning of Canadian securities legislation and the United States Securities Litigation Reform Act of 1995. Such forward-looking statements concern the Company's anticipated results and developments in the Company's operations in future periods, planned exploration and development of its properties, plans related to its business and other matters that may occur in the future. These statements relate to analyses and other information that are based on expectations of future performance, including silver and gold production and planned work programs. Statements concerning reserves and mineral resource estimates may also constitute forward-looking statements to the extent that they involve estimates of the mineralization that will be encountered if the property is developed and, in the case of mineral reserves, such statements reflect the conclusion based on certain assumptions that the mineral deposit can be economically exploited.
Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements, including, without limitation: risks related to precious and base metal price fluctuations; risks related to fluctuations in the currency markets (particularly the Mexican peso, Canadian dollar and United States dollar); risks related to the inherently dangerous activity of mining, including conditions or events beyond our control, and operating or technical difficulties in mineral exploration, development and mining activities; uncertainty in the Company's ability to raise financing and fund the exploration and development of its mineral properties; uncertainty as to actual capital costs, operating costs, production and economic returns, and uncertainty that development activities will result in profitable mining operations; risks related to reserves and mineral resource figures being estimates based on interpretations and assumptions which may result in less mineral production under actual conditions than is currently estimated and to diminishing quantities or grades of mineral reserves as properties are mined; risks related to governmental regulations and obtaining necessary licenses and permits; risks related to the business being subject to environmental laws and regulations which may increase costs of doing business and restrict our operations; risks related to mineral properties being subject to prior unregistered agreements, transfers, or claims and other defects in title; risks relating to inadequate insurance or inability to obtain insurance; risks related to potential litigation; risks related to the global economy; risks related to the Company's status as a foreign private issuer in the United States; risks related to all of the Company's properties being located in Mexico and El Salvador, including political, economic, social and regulatory instability; and risks related to officers and directors becoming associated with other natural resource companies which may give rise to conflicts of interests. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the forward-looking statements. The Company's forward-looking statements are based on beliefs, expectations and opinions of management on the date the statements are made. For the reasons set forth above, investors should not place undue reliance on forward-looking statements.
The information provided in this news release is not intended to be a comprehensive review of all matters and developments concerning the Company. It should be read in conjunction with all other disclosure documents of the Company. The information contained herein is not a substitute for detailed investigation or analysis. No securities commission or regulatory authority has reviewed the accuracy or adequacy of the information presented.
J. Scott Drever, President
SILVERCREST MINES INC.
Neither TSX Venture Exchange nor its Regulation Services Provider (as defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact:
SilverCrest Mines Inc.
Fred Cooper
(604) 694-1730 ext. 108
Toll Free: 1-866-691-1730
(604) 694-1761 (FAX)
info@silvercrestmines.com
www.silvercrestmines.com
Disclaimer: Investorideas.com does not make stock recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Silvercrest Mines has compensated Investorideas for annual news publication and distribution and company profile: nine thousand seven hundred starting August 2012
More info: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

China Stock News Alert: China Nuokang Bio-Pharmaceutical (NASDAQ: NKBP) Gains on Going Private Deal

New York, New York - September 27, 2012 (Investorideas.com newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector research for independent investors issues a trading alert for China Nuokang Bio-Pharmaceutical Inc. (NASDAQ: NKBP), one of the top gainers on NASDAQ in morning trading. The stock is trading at $5.2692, gaining 0.4892 or 10.23% as of 11:34AM EDT.

The Company announced today that it has entered into an Agreement and Plan of Merger with Kingbird Investment Inc. ("Parent"), a Cayman Islands exempted company with limited liability and beneficially owned by Ms. Yuhuan Zhu, the wife of Mr. Baizhong Xue, the Company's Chairman and Chief Executive Officer, and Kingbird Mergerco. Inc., a Cayman Islands exempted company with limited liability and a direct wholly-owned subsidiary of Parent ("Merger Sub").
This is one of many China companies that has announced a going private deal in the past year.
China Nuokang Bio-Pharmaceutical Inc. (NKBP) is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hospital-based medical products. The Company provides a diversified portfolio of products across more than 4,200 hospitals in China. Nuokang's principal products include Baquting(R), China's leading hemocoagulase product by market share, Kaitong(R), a lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis; and alpha lipoic acid capsules, or ALA, an antioxidant product that addresses diabetic neuropathy. The Company's product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. www.nkbp.com
About NASDAQ
http://www.nasdaq.com/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/ Resources/Newsletter.asp
Become an Investorideas.com Member and access our 13 online stock directories 24/7 - water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Investorideas.com Launches "Share of the Universe", the Only Share Certificate to Never Lose Value

New York, New York - September 26, 2012 (www.investorideas.com newswire) Investorideas.com, an investor research portal specializing in sector for independent investors launches , Shares of the Universe, a new concept in giving and giving back to the Universe.
The idea, based on the stock market with shares going up and down, is to create and give a share certificate that can never lose value.
Each share of the universe certifies that the recipient is entitled to one share of the Universe and is entitle to all the rights and privileges if offers. Unlike publicly traded companies, there are an unlimited number of shares available.
Each certificate is in PDF format and can be emailed or printed and framed. Full size is 11.69 x 8.27 inches. Shares can be purchased by Paypal for $9.97 with $2.00 of each purchase to be donated back to charity or non- profit of choice.
Learn more: http://www.investorideas.com/Share-of-the-Universe.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online stock directories 24/7 - water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Biotech Stock Trading Alert: Sunshine Biopharma (OTCBB: SBFM) Gains

New York, New York - September 26, 2012 (Investorideas.com Newswire, www.biotechindustrystocks.com) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks issues a trading alert for Sunshine Biopharma Inc. (OTCBB: SBFM) . The stock is trading at $ 0.31, up 0.03 or 10.71% as of 1:42PM EDT on over 86,000 shares, with a day high of $0.34.
The Company reported news yesterday that that its paper on Adva-27a preclinical research results has been accepted and will be published in the October issue of ANTICANCER RESEARCH, a peer-reviewed International Journal of Cancer Research and Treatment.
Full news: http://www.investorideas.com/CO/SBFM/news/2012/09251.asp
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.

www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Announces the Appointment of Dr. Stephen Z. Fadem to its Extracorporeal Science Advisory Board

SAN DIEGO - September 26, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), announced today that Dr. Stephen Z. Fadem has agreed to join the company's Extracorporeal Science Advisory Board. Dr. Fadem is active as a practicing Houston nephrologist, teacher, lecturer and researcher. He began practice in 1978 after completing a renal fellowship at The University of Texas Health Science Center in San Antonio. He is a graduate of the University of Oklahoma College of Medicine, and did his internal medicine residency at The University of Texas and MD Anderson Hospital in Houston. He is a Clinical Professor of Medicine, Baylor College of Medicine.

Dr. Fadem is also a Fellow of the American College of Physicians, Fellow of the American Society of Nephrology and diplomate of the American Board of Quality Assurance and Utilization Review Physicians. He has served as the Chairman of the (National Kidney Foundation (NKF) of Southeast Texas Medical Advisory Board, and has received their Lifetime Achievement Award and the Myron L. Jenkins Award.
On a national level, Dr. Fadem is co-chairman of the Medical Advisory Board of the American Association of Kidney Patients (AAKP), and a past vice-president of the AAKP Board of Directors. He has also served on the Board of Directors of the Renal Physicians Association, and actively serves on two national RPA committees, the Government Affairs Committee and the Health Finance Committee. Dr. Fadem has been active in the Forum of ESRD Networks, was a member of the CMS Clinical Performance Measures Committee. He serves as a consultant to the computer industry in the development of CKD management software and is the founder of Touchcalc, a software design company. He lectures frequently on dialysis management, preventive nephrology, vascular calcification, anemia, patient education, CKD education, and computer technology and computer security. Dr. Fadem is the co-editor of AAKP Renalife, and is a reviewer for several peer-reviewed journals.
Dr. Fadem has been nationally recognized, receiving the AAKP Nova Award, the NKF Distinguished Service Award. He has also received the NKF Presidents Award. He has been awarded the Peter Lundin Award for his contributions to patient education and The Visionary Award for his contributions to CKD education. He has also been named as one of America's Top Doctors by Castle Connolly and US News and World Report.

About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

NASDAQ Morning Mover: Life Partners (NASDAQ: LPHI) Gains 95% on Ruling

New York, New York –September 26, 2012 – (www.investorideas.com newswire, ) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector for independent investors issues a trading alert for Life Partners Holdings, Inc. (NASDAQ: LPHI), the top percentage gainer on NASDAQ in morning trading, currently at $2.85 , gaining 1.39 or 95.21% as of  11:00AM EDT  on over 2.9 Millions shares.

The stock moved on news that Travis County District Judge Stephen Yelenosky ruled that the life settlement transactions that it facilitates are not securities under Texas law.

Life Partners CEO, Brian Pardo, expressed gratitude for the integrity of the judicial system. “The Attorney General brought this case knowing that both a Federal Court of Appeals and a Texas appeals court have ruled specifically that Life Partners’ life settlements are not securities. The Attorney General has issued inflammatory press releases and used this suit as a vehicle to make baseless claims of fraud, insolvency and a lack of regulation. None of that is true. We have been in business for 20 years. We have facilitated over 143,000 purchaser transactions involving over 6,500 policies totaling over $3 billion in face value.”



Life Partners Holdings, Inc. (NASDAQ: LPHI) is a financial services company and the parent company of Life Partners, Inc. (“LPI”), one of the oldest and most active companies in the United States engaged in the secondary market for life insurance known generally as “life settlements.” 

About NASDAQ
http://www.nasdaq.com/

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .  
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com


Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp

Become an Investorideas.com Member and access our 14 online stock directories 24/7 – water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/


Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source – www.Investorideas.com